+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

ALK-Abello AS (ALK B) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 55 Pages
  • April 2023
  • GlobalData
  • ID: 1292311
ALK-Abello AS (ALK B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

ALK-Abello AS (ALK), a subsidiary of The Lundbeck Foundation, discovers, develops, and commercializes immunotherapies to treat and prevent allergies. The company's allergy immunotherapy product portfolio includes tablets, sublingual or drop-based vaccines, subcutaneous vaccines, and adrenaline auto-injectors to treat severe allergic reactions in emergencies (anaphylaxis). ALK’s research and development pipeline products include sublingual immunotherapy tablets for addressing ragweed, house dust mite, and tree pollen allergy. The company’s products target allergies caused by grass, tree, ragweed, house dust mite, Japanese cedar, and venom. The company has subsidiaries in Europe, North America, and Asia-Pacific. ALK is headquartered in Horsholm, Denmark.

ALK-Abello AS Key Recent Developments

  • Mar 28, 2023: ALK appoints Claus Steensen Solje as new Chief Financial Officer (CFO)
  • Mar 23, 2023: ALK-Abello Notice of Annual General Meeting in 2023
  • Mar 23, 2023: Annual General Meeting in ALK-Abelló A/S held on 23 March 2023
  • Feb 27, 2023: ALK Notice of Annual General Meeting

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • ALK-Abello AS - Key Facts
  • ALK-Abello AS - Key Employees
  • ALK-Abello AS - Key Employee Biographies
  • ALK-Abello AS - Major Products and Services
  • ALK-Abello AS - History
  • ALK-Abello AS - Company Statement
  • ALK-Abello AS - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • ALK-Abello AS - Business Description
  • Product Category: Other Products and Services
  • Overview
  • Performance
  • Product Category: SCIT/SLIT drops
  • Overview
  • Performance
  • Product Category: SLIT tablets
  • Overview
  • Performance
  • Geographical Segment: Europe
  • Target Markets
  • Performance
  • Geographical Segment: International Markets
  • Target Markets
  • Performance
  • Geographical Segment: North America
  • Performance
  • R&D Overview
  • ALK-Abello AS - Corporate Strategy
  • ALK-Abello AS - SWOT Analysis
  • SWOT Analysis - Overview
  • ALK-Abello AS - Strengths
  • ALK-Abello AS - Weaknesses
  • ALK-Abello AS - Opportunities
  • ALK-Abello AS - Threats
  • ALK-Abello AS - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • ALK-Abello AS, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Mar 28, 2023: ALK appoints Claus Steensen Solje as new Chief Financial Officer (CFO)
  • Mar 23, 2023: ALK-Abello Notice of Annual General Meeting in 2023
  • Mar 23, 2023: Annual General Meeting in ALK-Abelló A/S held on 23 March 2023
  • Feb 27, 2023: ALK Notice of Annual General Meeting
  • Feb 27, 2023: Annual General Meeting in ALK on 23 March 2023
  • Feb 03, 2023: ALK delivers sales growth of 13% with profits up 33% in 2022
  • Dec 21, 2022: Henriette Mersebach to succeed Henrik Jacobi as Executive Vice President, R&D at ALK
  • Nov 03, 2022: Release date of nine-month interim report (Q3) 2022 for ALK and audio cast
  • Aug 11, 2022: ALK-Abello Announces Six-month interim report (Q2) 2022
  • Aug 04, 2022: Release date of six-month interim report (Q2) 2022 for ALK and audio cast
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • ALK-Abello AS, Key Facts
  • ALK-Abello AS, Key Employees
  • ALK-Abello AS, Key Employee Biographies
  • ALK-Abello AS, Major Products and Services
  • ALK-Abello AS, History
  • ALK-Abello AS, Other Locations
  • ALK-Abello AS, Subsidiaries
  • ALK-Abello AS, Key Competitors
  • ALK-Abello AS, Ratios based on current share price
  • ALK-Abello AS, Annual Ratios
  • ALK-Abello AS, Interim Ratios
  • ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • ALK-Abello AS, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • ALK-Abello AS, Performance Chart (2018 - 2022)
  • ALK-Abello AS, Ratio Charts
  • ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • ALK-Abello AS, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Synairgen Plc
  • Stallergenes Greer Ltd
  • Niox Group Plc
  • Allergy Therapeutics Plc
  • Allergopharma GmbH & Co KG
  • Synairgen Plc
  • Stallergenes Greer Ltd
  • Allergy Therapeutics Plc
  • Circassia Group Plc
  • Allergopharma GmbH & Co KG